ArticleInternational journal of technology assessment in health care2024

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.

Srinivas Teppala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.